CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?

Key Takeaways CRMD's DefenCath sales hit $167.6M in the first nine months of 2025, driving the stock's YTD surge.Higher outpatient utilization and planned label expansion are expected to support DefenCath growth.The $300M Melinta deal adds seven therapies and diversified opportunities, including Rezzayo.Shares of CorMedix (CRMD) have witnessed a strong surge so far this year, primarily driven by the continued strong uptake of the company’s lead marketed therapy, DefenCath (Taurolidine + Heparin). The stock ...